Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTASEL1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 7	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 8	JAN 29	PHAR reloaded with new search and display fields
NEWS 9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13	FEB 26	MEDLINE reloaded with enhancements
NEWS 14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19	MAR 16	CASREACT coverage extended
NEWS 20	MAR 20	MARPAT now updated daily
NEWS 21	MAR 22	LWPI reloaded
NEWS 22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 26	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 28	MAY 01	New CAS web site launched
NEWS 29	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 30	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 31	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 32	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 33	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 34	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:14:26 ON 15 JUN 2007

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:14:36 ON 15 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2007 HIGHEST RN 937362-79-3
DICTIONARY FILE UPDATES: 14 JUN 2007 HIGHEST RN 937362-79-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10561545.str



chain nodes :
12 13 14 15 16 17 18 19 20 21 22 24 28 33

ring nodes :
1 2 3 4 5 6 7 8 9 10 11 23 25 26 27 29 30 31 32
chain bonds :
1-14 4-7 5-13 8-12 9-19 14-15 14-17 15-16 15-18 19-20 19-24 20-21 21-22
22-23 22-28 24-25 30-33
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11 23-29 23-32 25-26
25-27 26-27 29-30 30-31 31-32
exact/norm bonds :
4-7 7-8 7-11 8-9 8-12 9-10 9-19 10-11 14-15 14-17 15-16 15-18 19-20
19-24 23-29 23-32 25-26 25-27 26-27 29-30 30-31 31-32
exact bonds :
1-14 5-13 20-21 21-22 22-23 22-28 24-25 30-33
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:Atom 24:CLASS 25:Atom 26:Atom
27:Atom 28:CLASS 29:Atom 30:Atom 31:Atom 32:Atom 33:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 12:14:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1 TO 80
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 12:14:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 71 TO ITERATE

100.0% PROCESSED 71 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=> fil reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'REGISTRY' ENTERED AT 12:15:04 ON 15 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2007 HIGHEST RN 937362-79-3
DICTIONARY FILE UPDATES: 14 JUN 2007 HIGHEST RN 937362-79-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10561545b.str



chain nodes :
12 13 14

ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
4-7 8-12 9-13 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11
exact/norm bonds :
4-7 7-8 7-11 8-9 8-12 9-10 9-13 10-11 13-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS

L4 STRUCTURE UPLOADED

=> d
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l4
SAMPLE SEARCH INITIATED 12:16:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 25 TO ITERATE

100.0% PROCESSED 25 ITERATIONS 20 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 200 TO 800
PROJECTED ANSWERS: 132 TO 668

L5 20 SEA SSS SAM L4

=> s l4 full
FULL SEARCH INITIATED 12:16:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 615 TO ITERATE

100.0% PROCESSED 615 ITERATIONS 483 ANSWERS
SEARCH TIME: 00.00.01

L6 483 SEA SSS FUL L4

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.55	344.86

FILE 'CAPLUS' ENTERED AT 12:16:30 ON 15 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Jun 2007 VOL 146 ISS 26
FILE LAST UPDATED: 14 Jun 2007 (20070614/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l6
L7 17 L6

=> d ibib abs hitstr tot

L7 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1354331 CAPLUS
DOCUMENT NUMBER: 146:93568
TITLE: MAO-B inhibitors useful for treating obesity
INVENTOR(S): McElroy, John F.; Chorvat, Robert J.; Rajagopalan, Parthasarathi
PATENT ASSIGNEE(S): Jenrin Discovery, USA
SOURCE: PCT Int. Appl., 109pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006138475	A2	20061228	WO 2006-US23337	20060615
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2007078172	A1	20070405	US 2006-424274	20060615
PRIORITY APPLN. INFO.:			US 2005-691323P P	20050616
			US 2006-798467P P	20060508

OTHER SOURCE(S): MARPAT 146:93568

AB The invention provides a method of treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance) in a mammal by administering to the mammal a therapeutically effective amount of a MAO-B inhibitor.

IT 676232-70-5 676232-73-8 676232-74-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MAO-B inhibitors useful for treating obesity)

RN 676232-70-5 CAPLUS
CN Methanesulfonamide, N-[(3S)-2-oxo-1-[4-(phenylmethoxy)phenyl]-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 676232-73-8 CAPLUS
CN Methanesulfonamide, N-[(3R)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

L7 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 676232-74-9 CAPLUS
CN Methanesulfonamide, N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

L7 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1093715 CAPLUS
DOCUMENT NUMBER: 145:438539
TITLE: Preparation of 3-sulfonylaminopyrrolidin-2-ones as factor Xa inhibitors.
INVENTOR(S): Harling, John David; Watson, Nigel Stephen; Young, Robert John
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 108pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006108709	A1	20061019	WO 2006-EP3774	20060407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			GB 2005-7287 A	20050411
			GB 2005-14491 A	20050714

OTHER SOURCE(S): MARPAT 145:438539

GI



I

AB Title compds. [I; R1 = (substituted) naphthalenyl, indolyl, benzothienyl, benzofuryl, thienylethenyl, thienylthienyl, etc.; R2 = (substituted) tetrahydroisoquinolyl, tetrahydrothiazolopyridyl, etc.; R10 = H, alkyl, aminocarbonylalkyl, alkoxycarbonylalkyl, carboxyalkyl, alkylcarbonyl], were prepared Thus, 6-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]-2-naphthalenesulfonamide hydrochloride [preparation starting from tert-Bu 6-amino-3,4-dihydro-2(1H)-isoquinolinecarboxylate, Z-Met-OH, and 6-chloro-2-naphthalenesulfonyl chloride given] inhibited factor Xa with IC50 <10 nM.

IT 912845-93-3P 912845-94-4P 912845-95-5P
912845-96-6P 912845-97-7P 912845-98-8P
912845-99-9P 912846-00-5P 912846-01-6P
912846-02-7P 912846-03-8P 912846-04-9P
912846-05-0P 912846-06-1P 912846-07-2P
912846-08-3P 912846-09-4P 912846-10-7P

912846-11-8P 912846-12-9P 912846-13-0P
912846-14-1P 912846-15-2P 912846-16-3P
912846-17-4P 912846-18-5P 912846-19-6P
912846-20-9P 912846-21-0P 912846-22-1P
912846-23-2P 912846-24-3P 912846-25-4P
912846-27-6P 912846-28-7P 912846-29-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compd.; prepn. of sulfonylaminopyrrolidinones as factor Xa inhibitors)

RN 912845-93-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912845-94-4 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 912845-95-5 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 912846-00-5 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-2-methyl-6-isoquinolinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-01-6 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-02-7 CAPLUS
CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-03-8 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 912845-96-6 CAPLUS
CN 1H-Indole-6-sulfonamide, 3-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912845-97-7 CAPLUS
CN 1H-Indole-6-sulfonamide, N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912845-98-8 CAPLUS
CN 1H-Indole-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912845-99-9 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-2-methyl-6-isoquinolinyl)-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.



RN 912846-04-9 CAPLUS
CN 2-Thiopheneethanesulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-05-0 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 912846-06-1 CAPLUS
CN 1H-Indole-6-sulfonamide, 3-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-07-2 CAPLUS
CN 1H-Indole-6-sulfonamide, N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-08-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3R)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-09-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-(5-fluoro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-13-0 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-(7-fluoro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-14-1 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-(7-fluoro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 912846-15-2 CAPLUS
CN 1H-Indole-6-sulfonamide, 3-chloro-N-[(3S)-1-(7-fluoro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-10-7 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-(5-fluoro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 912846-11-8 CAPLUS
CN 1H-Indole-6-sulfonamide, 3-chloro-N-[(3S)-1-(5-fluoro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-12-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-(7-fluoro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-16-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-(7-chloro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-17-4 CAPLUS
CN Ethenesulfonamide, N-[(3S)-1-(7-chloro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 912846-18-5 CAPLUS
CN 1H-Indole-6-sulfonamide, 3-chloro-N-[(3S)-1-(7-chloro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-19-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-7-methyl-6-isoquinolinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-20-9 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-7-methyl-6-isoquinolinyl)-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 912846-21-0 CAPLUS
CN 1H-Indole-6-sulfonamide, 3-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-7-methyl-6-isoquinolinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-25-4 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-methyl-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 912846-27-6 CAPLUS
CN 1H-Indole-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-28-7 CAPLUS
CN Ethenesulfonamide, 2-(4-chlorophenyl)-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-2-methyl-6-isoquinolinyl)-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 912846-29-8 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-3-methyl-6-isoquinolinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 912846-22-1 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-1-methyl-6-isoquinolinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-23-2 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-1-methyl-6-isoquinolinyl)-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 912846-24-3 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-3-methyl-6-isoquinolinyl)-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

Absolute stereochemistry.



IT 912847-11-1P 912847-12-2P 912847-13-3P
912847-14-4P 912847-15-5P 912847-16-6P
912847-17-7P 912847-18-8P 912847-20-2P
912847-22-4P 912847-23-5P 912847-24-6P
912847-25-7P 912847-26-8P 912847-27-9P
912847-28-0P 912847-29-1P 912847-30-4P
912847-31-5P 912847-32-6P 912847-33-7P
912847-34-8P 912847-35-9P 912847-36-0P
912847-37-1P 912847-38-2P 912847-39-3P
912847-40-6P 912847-41-7P 912847-42-8P
912847-43-9P 912847-44-0P 912847-45-1P
912847-47-3P 912847-48-4P 912847-49-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonylaminopyrrolidinones as factor Xa inhibitors)

RN 912847-11-1 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 912847-12-2 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]-, monohydrochloride, (1E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 912847-13-3 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 912847-16-6 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]-1H-indole-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 912845-98-8
CMF C21 H21 Cl N4 O3 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 912847-17-7 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-2-methyl-6-isoquinolinyl)-3-pyrrolidinyl]ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 912845-99-9
CMF C20 H22 Cl N3 O3 S2



● HCl

RN 912847-14-4 CAPLUS
CN Formic acid, compd. with 3-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]-1H-indole-6-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 912845-96-6
CMF C21 H21 Cl N4 O3 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 912847-15-5 CAPLUS
CN Formic acid, compd. with N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]-1H-indole-6-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 912845-97-7
CMF C21 H22 N4 O3 S

Absolute stereochemistry.

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 912847-18-8 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-2-methyl-6-isoquinolinyl)-3-pyrrolidinyl]benzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 912846-00-5
CMF C22 H22 Cl N3 O3 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 912847-20-2 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 912846-01-6
CMF C21 H20 Cl N3 O3 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 912847-22-4 CAPLUS
CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 912847-23-5 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 912847-24-6 CAPLUS
CN 2-Thiopheneethanesulfonamide, 5-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 912847-25-7 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-3-pyrrolidinyl]-, monohydrochloride, (1E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 912847-26-8 CAPLUS
CN Formic acid, compd. with 3-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-3-pyrrolidinyl]-1H-indole-6-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 912846-06-1
CMF C21 H21 Cl N4 O3 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 912847-27-9 CAPLUS
CN Formic acid, compd. with N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-3-pyrrolidinyl]-1H-indole-6-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 912846-07-2
CMF C21 H22 N4 O3 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 912847-28-0 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-(5-fluoro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 912847-29-1 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-(5-fluoro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]-, monohydrochloride, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 912847-30-4 CAPLUS
CN 1H-Indole-6-sulfonamide, 3-chloro-N-[(3S)-1-(5-fluoro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 912847-31-5 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-(7-fluoro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 912847-32-6 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-(7-fluoro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.



● HCl

RN 912847-36-0 CAPLUS
CN Ethenesulfonamide, N-[(3S)-1-(7-chloro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, monohydrochloride, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 912847-37-1 CAPLUS
CN 1H-Indole-6-sulfonamide, 3-chloro-N-[(3S)-1-(7-chloro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 912847-33-7 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-(7-fluoro-1,2,3,4-tetrahydro-6-isoquinolinyl]-2-oxo-3-pyrrolidinyl]-, monohydrochloride, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 912847-34-8 CAPLUS
CN 1H-Indole-6-sulfonamide, 3-chloro-N-[(3S)-1-(7-fluoro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 912847-35-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-(7-chloro-1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 912847-38-2 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-7-methyl-6-isoquinolinyl)-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 912847-39-3 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-7-methyl-6-isoquinolinyl)-3-pyrrolidinyl]-, monohydrochloride, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 912847-40-6 CAPLUS
CN 1H-Indole-6-sulfonamide, 3-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-7-methyl-6-isoquinolinyl)-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 912847-41-7 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-2-oxo-1-[1,2,3,4-tetrahydro-2-(1-methylethyl)-6-isoquinolinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912847-42-8 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-1-



● HCl

RN 912847-45-1 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-methyl-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]-, monohydrochloride, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 912847-47-3 CAPLUS
CN Formic acid, compd. with 5-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-6-isoquinolinyl)-3-pyrrolidinyl]-1H-indole-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 912846-27-6
CMF C21 H21 Cl N4 O3 S

Absolute stereochemistry.



CM 2

CRN 64-18-6

methyl-6-isoquinolinyl)-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 912847-43-9 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-1-methyl-6-isoquinolinyl)-3-pyrrolidinyl]-, monohydrochloride, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 912847-44-0 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-3-methyl-6-isoquinolinyl)-3-pyrrolidinyl]-, monohydrochloride, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

CMF C H2 O2

RN 912847-48-4 CAPLUS
CN Formic acid, compd. with (1E)-2-(4-chlorophenyl)-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-2-methyl-6-isoquinolinyl)-3-pyrrolidinyl]ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 912846-28-7
CMF C22 H24 Cl N3 O3 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 912847-49-5 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-2-oxo-1-(1,2,3,4-tetrahydro-3-methyl-6-isoquinolinyl)-3-pyrrolidinyl]-2-naphthalenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 912846-29-8
CMF C24 H24 Cl N3 O3 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

IT 912846-34-5P 912846-35-6P 912846-36-7P
912846-37-8P 912846-38-9P 912846-39-0P
912846-40-3P 912846-44-7P 912846-45-8P
912846-47-0P 912846-48-1P 912846-49-2P
912846-50-5P 912846-51-6P 912846-52-7P
912846-59-4P 912846-60-7P 912846-61-8P
912846-62-9P 912846-70-9P 912846-71-0P
912846-72-1P 912846-73-2P 912846-78-7P
912846-79-8P 912846-80-1P 912846-83-4P
912846-84-5P 912846-86-7P 912846-97-0P
912846-98-1P 912847-05-3P 912847-09-7P
912847-10-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonylaminopyrrolidinones as factor Xa inhibitors)

RN 912846-34-5 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-35-6 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 912846-36-7 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-37-8 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[[3-chloro-1-[tris(1-methylethyl)silyl]-1H-indol-6-yl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-38-9 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[(3-chloro-1H-indol-6-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-39-0 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-6-[(3S)-2-oxo-3-[[[1-[tris(1-methylethyl)silyl]-1H-indol-6-yl]sulfonyl]amino]-1-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-40-3 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[[6-chloro-1-[(1,1-dimethylethoxy)carbonyl]-1H-indol-2-yl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-44-7 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[(5-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-45-8 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-47-0 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 7-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-48-1 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 7-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-49-2 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 7-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 912846-50-5 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 7-[(3S)-3-[[[3-chloro-1-[tris(1-methylethyl)silyl]-1H-indol-6-yl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-60-7 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-5-fluoro-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 912846-61-8 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[[3-chloro-1-[tris(1-methylethyl)silyl]-1H-indol-6-yl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-5-fluoro-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-62-9 CAPLUS



RN 912846-51-6 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-7-[(3S)-2-oxo-3-[[[1-[tris(1-methylethyl)silyl]-1H-indol-6-yl]sulfonyl]amino]-1-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-52-7 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3R)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-59-4 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-5-fluoro-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[(3-chloro-1H-indol-6-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-5-fluoro-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-70-9 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-7-fluoro-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-71-0 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-7-fluoro-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-72-1 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-7-fluoro-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 912846-73-2 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[[3-chloro-1-[tris(1-methylethyl)silyl]-1H-indol-6-yl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-7-fluoro-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-78-7 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 7-chloro-6-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-79-8 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 7-chloro-6-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 912846-80-1 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 7-chloro-6-[(3S)-3-[[[3-chloro-1-[tris(1-methylethyl)silyl]-1H-indol-6-yl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-83-4 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-7-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-84-5 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-7-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 912846-86-7 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[[3-chloro-1-[tris(1-methylethyl)silyl]-1H-indol-6-yl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-7-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-97-0 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-1-methyl-,

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 912846-98-1 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-1-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 912847-05-3 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-3-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 912847-09-7 CAPLUS

L7 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 912847-10-0 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 6-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3,4-dihydro-3-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:236680 CAPLUS
DOCUMENT NUMBER: 144:311901
TITLE: Preparation of N-[1-(2,3-dihydro-1H-inden-5-yl)-2-oxo-3-pyrrolidinyl] sulfonamides as Factor Xa inhibitors
INVENTOR(S): Harling, John David; Kleanthous, Savvas; Watson, Nigel Stephen; West, Robert Ian; Young, Robert John
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006027186	A1	20060316	WO 2005-EP9517	20050902
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1786770	A1	20070523	EP 2005-781611	20050902
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				

PRIORITY APPLN. INFO.: GB 2004-19744 A 20040906
WO 2005-EP9517 W 20050902
OTHER SOURCE(S): MARPAT 144:311901
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [R1 = II-VII (wherein each ring optionally contains a further heteroatom N; Z = optional substituent halogen; alk = alkylene or alkenylene; T = S, O or NH); R2 = H, alkyl, alkyl(CONRaRb), alkylCO2(alkyl), CO2(alkyl) or alkyl(CO2H); Ra, Rb = H, alkyl, or together with the N atom to which they are bonded form a 5-7 membered non-aromatic heterocyclic ring optionally containing an addnl. heteroatom selected from O, N and S; n = 0-2; X = an optional substituent on the indane ring selected from halo, alkyl, alkenyl and CF3; Y = (CH2)mNRcRd ; Rc, Rd = H, alkyl, alkyl(OH), or together with the N atom to which they are bonded form a 4-7 membered non-aromatic heterocyclic ring; m = 0-2; and pharmaceutically acceptable derivative(s) thereof], useful as Factor Xa inhibitors, were prepared
E.g., a multi-step synthesis of VIII.HCl, starting from 5-aminoindan-1-one, was given. All exemplified compds. I were found to exhibit Factor Xa inhibitory activity (Ki of <0.1 μM). The invention also relates to processes for the preparation of compds. I, pharmaceutical compns. containing compds. I and to the use of compds. I in medicine,

L7 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
particularly in the amelioration of a clin. condition for which a Factor Xa inhibitor is indicated.
IT 879499-79-3P 879499-80-6P 879499-81-7P
879499-82-8P 879499-83-9P 879499-84-0P
879499-85-1P 879499-86-2P 879499-87-3P
879499-88-4P 879499-89-5P 879499-90-8P
879500-18-2P 879500-20-6P 879500-21-7P
879500-22-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[1-(2,3-dihydro-1H-inden-5-yl)-2-oxo-3-pyrrolidinyl] sulfonamides as Factor Xa inhibitors)
RN 879499-79-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 879499-80-6 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[1-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]-, monohydrochloride, (1E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 879499-81-7 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[1-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 879499-82-8 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879499-83-9 CAPLUS
CN 1H-Indole-6-sulfonamide, 3-chloro-N-[(3S)-1-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879499-84-0 CAPLUS

L7 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 2-Thiopheneethanesulfonamide, 5-chloro-N-[(3S)-1-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879499-85-1 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2,3-dihydro-1-(methylamino)-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879499-86-2 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2,3-dihydro-1-(methylamino)-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 879499-87-3 CAPLUS
CN 2-Thiopheneethanesulfonamide, 5-chloro-N-[(3S)-1-[2,3-dihydro-1-(methylamino)-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 879499-88-4 CAPLUS
CN 1H-Indole-6-sulfonamide, 3-chloro-N-[(3S)-1-[2,3-dihydro-1-(methylamino)-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879499-89-5 CAPLUS
CN 2-Naphthalenesulfonamide, N-[(3S)-1-(1-amino-2,3-dihydro-1H-inden-5-yl)-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879499-90-8 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2,3-dihydro-1-(methylamino)-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879500-18-2 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[(1R)-1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CM 1

CRN 879500-17-1
CMF C25 H26 Cl N3 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 879500-20-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[(1S)-1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 879500-19-3
CMF C25 H26 Cl N3 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L7 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 879500-21-7 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 879500-22-8 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[1-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 879500-01-3P 879500-05-7P 879500-06-8P
879500-07-9P 879500-08-0P 879500-09-1P
879500-13-7P 879500-14-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-[1-(2,3-dihydro-1H-inden-5-yl)-2-oxo-3-pyrrolidinyl] sulfonamides as Factor Xa inhibitors)
RN 879500-01-3 CAPLUS
CN 1H-Indole-6-sulfonamide, 3-chloro-N-[(3S)-1-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]-1-[tris(1-methylethyl)silyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879500-05-7 CAPLUS
CN Acetamide, N-[5-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-2,3-dihydro-1H-inden-1-yl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879500-06-8 CAPLUS
CN Acetamide, N-[5-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-2,3-dihydro-1H-inden-1-yl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 879500-07-9 CAPLUS
CN Acetamide, N-[5-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-2,3-dihydro-1H-inden-1-yl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 879500-13-7 CAPLUS
CN Acetamide, N-[5-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-2,3-dihydro-1H-inden-1-yl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879500-14-8 CAPLUS
CN Acetamide, N-[5-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-2,3-dihydro-1H-inden-1-yl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Absolute stereochemistry.



RN 879500-08-0 CAPLUS
CN Acetamide, N-[5-[(3S)-3-[[[3-chloro-1-[tris(1-methylethyl)silyl]-1H-indol-6-yl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-2,3-dihydro-1H-inden-1-yl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879500-09-1 CAPLUS
CN Acetamide, N-[5-[(3S)-3-[[(3-chloro-1H-indol-6-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-2,3-dihydro-1H-inden-1-yl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

ACCESSION NUMBER: 2005:394818 CAPLUS
DOCUMENT NUMBER: 142:447111
TITLE: Preparation of sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
INVENTOR(S): Han, Wei; Hu, Zilun; Gungor, Timur
PATENT ASSIGNEE(S): Bristol Myers Squibb Company, USA
SOURCE: U.S. Pat. Appl. Publ., 120 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005096309	A1	20050505	US 2004-952396	20040928
US 7169795	B2	20070130		
WO 2005048922	A2	20050602	WO 2004-US31774	20040929
WO 2005048922	A3	20070104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1667635	A2	20060614	EP 2004-817779	20040929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 2007099922	A1	20070503	US 2006-611195	20061215

PRIORITY APPLN. INFO.: US 2003-507177P P 20030930
US 2004-952396 A 20040928
WO 2004-US31774 W 20040929

OTHER SOURCE(S): MARPAT 142:447111
GI



AB The present application describes sulfonylaminovalerolactams and derivs. thereof of formula I-VI or pharmaceutically acceptable salt forms thereof [wherein the central lactam ring is optionally substituted; ring G = (un)substituted mono- or bicyclic carbocycle or heterocycle; X = SO2, (un)substituted NH; G1 = H, cyano, each (un)substituted (CH2)1-2-C(O)H, NH2, (CH2)2-5-NH2, (CH2)2-5-OH, C1-6 alkyl, etc.; G2 = (un)substituted CH2CH2 or CH:CH; A = each (un)substituted C3-10 cycloalkyl, C3-10 cycloalkenyl, or 4- to 12-membered heterocyclyl; B = cyano, (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, etc.]. These compds. are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa, for treating thromboembolic disorders which is selected from arterial or venous cardiovascular thromboembolic disorders. Thus, reductive amination of cyclopentanone by (S)-6-chloronaphthalene-2-sulfonic acid N-(2-oxo-[1,4']bipiperidinyl-3-yl)amide and sodium cyanoborohydride in THF at room temperature for 5 h gave (S)-6-chloronaphthalene-2-sulfonic acid N-(1'-cyclopentyl-2-oxo-[1,4']bipiperidinyl-3-yl)amide. The compds. I inhibited factor Xa with Ki of ≤10 μM. Some of the compds. I also inhibited human thrombin with ki of ≤10 μM.

IT 851120-39-3P, (S)-N-[4-[3-[[(2-Chloronaphthalen-6-yl)sulfonyl]amino]-2-oxopyrrolidin-1-yl]phenyl]-2-(dimethylamino)-N-methylacetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonylaminovalerolactams and derivs. thereof as factor Xa inhibitors for treating thromboembolic disorders)

RN 851120-39-3 CAPLUS

CN Acetamide, N-[4-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]phenyl]-2-(dimethylamino)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:57643 CAPLUS
DOCUMENT NUMBER: 142:159496
TITLE: Semiconductor for photoelectric conversion material, photoelectric converter, and photoelectrochemical cell
INVENTOR(S): Otsu, Shinya; Ofuku, Koji; Kagawa, Nobuaki
PATENT ASSIGNEE(S): Konica Minolta Holdings, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 31 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005019124	A	20050120	JP 2003-180739	20030625
PRIORITY APPLN. INFO.:			JP 2003-180739	20030625

OTHER SOURCE(S): MARPAT 142:159496
GI



AB The semiconductor contains a heterocyclic compound I (R1, R2, R3 = H or substituent; R1 and R2, R2 and R3 may form a ring; R4 = H, carboxyl, or -L-(CO2H)m group; L = bivalent linking group; m = 0 or 1; J1 = aliphatic, aromatic, or heterocyclic group; X = O or S; Z1 = aromatic C or heterocyclic ring; and n = 0 or 1) or II (R1', R2', R3' = H or substituent; R1' and R2', R2' and R3' may form a ring; X = O or S; Z1, Z2 = residue group necessary for forming aromatic C or heterocyclic ring; and n', m' = 0 or 1). The photoelec. converter has a layer of the above semiconductor on a conductive support. The photoelectrochem. cell has the above photoelec. converter, a charge transporting layer, and a counter electrode.

IT 827609-72-3
RL: MOA (Modifier or additive use); USES (Uses)
(semiconductors containing heterocyclic compds. for photoelec. converters in photoelectrochem. cells)

RN 827609-72-3 CAPLUS

CN Benzoic acid, 4-[3-[5-(dimethylamino)-2-thienyl]-2,5-dihydro-2,5-dioxo-4-[(phenylsulfonyl)amino]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1127376 CAPLUS
DOCUMENT NUMBER: 142:74569
TITLE: Preparation of 3-sulfonylamino-pyrrolidine-2-one derivatives as factor Xa inhibitors
INVENTOR(S): Borthwick, Alan David; Kelly, Henry Anderson; Watson, Nigel Stephen; Young, Robert John
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004111045	A1	20041223	WO 2004-EP6603	20040617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1641786	A1	20060405	EP 2004-740049	20040617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006527731	T	20061207	JP 2006-515993	20040617
US 2006167079	A1	20060727	US 2005-561414	20051219
PRIORITY APPLN. INFO.:			GB 2003-14373 A	20030619
			WO 2004-EP6603 W	20040617

OTHER SOURCE(S): MARPAT 142:74569
GI



I II

AB Title compds. represented by the formula I [wherein R1 = (un)substituted naphthyl, benzofuryl, phenyl(alkyl), etc.; R2 = H, alkyl, alkylamido,

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2

CRN 64-18-6
CMF C H2 O2

RN 811794-80-6 CAPLUS
CN 2-Thiopheneethanesulfonamide, N-[(3S)-1-[4-[2-(1-azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811794-81-7 CAPLUS
CN Formic acid, compd. with N-[(3S)-1-[4-[2-(1-azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-5-chloro-2-thiopheneethanesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-80-6
CMF C23 H25 Cl F N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
carbonylalkyl, etc.; X = (un)substituted Ph or arom. heterocyclic group; Y = (un)substituted Ph or arom. heterocyclic group; and pharmaceutically acceptable derivs. thereof] were prepd. as inhibitors of factor Xa. For example, II was given in a multi-step synthesis starting from the reaction of 2-fluoro-4-iodoaniline with tert-Bu ((3S)-tetrahydro-2-oxo-3-furanyl)carbamate. The prepd. compds. showed activity in vitro assay for inhibition of factor Xa with Ki values of less than 100 nM. Thus, I and their pharmaceutical compns. are useful medicine, particularly in the amelioration of a clin. condition for which a factor Xa inhibitor is indicated (no data).

IT 811794-78-2P 811794-79-3P 811794-80-6P
811794-81-7P 811794-82-8P 811794-83-9P
811794-84-0P 811794-85-1P 811794-86-2P
811794-87-3P 811794-88-4P 811794-89-5P
811794-90-8P 811794-91-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-(imidazolyl)phenyl-3-(sulfonylamino)pyrrolidin-2-one derivs. as factor Xa inhibitors)

RN 811794-78-2 CAPLUS
CN 1-Propene-1-sulfonamide, N-[(3S)-1-[4-[2-(1-azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811794-79-3 CAPLUS
CN Formic acid, compd. with (1E)-N-[(3S)-1-[4-[2-(1-azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-1-propene-1-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-78-2
CMF C24 H25 Cl F N5 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 811794-82-8 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, N-[(3S)-1-[4-[2-(1-azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811794-83-9 CAPLUS
CN Formic acid, compd. with N-[(3S)-1-[4-[2-(1-azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-6-chlorobenzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-82-8
CMF C25 H23 Cl F N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 811794-84-0 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[2-[(3-fluoro-1-pyrrolidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811794-85-1 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[2-[(3-fluoro-1-pyrrolidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-84-0
CMF C24 H24 Cl F2 N5 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811794-86-2 CAPLUS
CN 1-Propene-1-sulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[2-[(3-fluoro-1-pyrrolidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 811794-89-5 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[2-fluoro-4-[2-[(3-fluoro-1-pyrrolidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]benzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-88-4
CMF C26 H24 Cl F2 N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811794-90-8 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-[2-[(3-methoxy-1-azetidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811794-91-9 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[2-fluoro-4-[2-[(3-methoxy-1-azetidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]benzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-90-8



RN 811794-87-3 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[2-[(3-fluoro-1-pyrrolidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]-1-propene-1-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-86-2
CMF C25 H26 Cl F2 N5 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811794-88-4 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-[2-[(3-fluoro-1-pyrrolidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



CMF C26 H25 Cl F N5 O4 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1127332 CAPLUS
DOCUMENT NUMBER: 142:74444
TITLE: Preparation of 3-sulfonylamino-pyrrolidine-2-one derivatives as factor Xa inhibitors
INVENTOR(S): Borthwick, Alan David; Harling, John David; Irving, Wendy Rebecca; Kleanthous, Savvas; Watson, Nigel Stephen; Young, Robert John
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110997	A1	20041223	WO 2004-EP6604	20040617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1641752	A1	20060405	EP 2004-740050	20040617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006527732	T	20061207	JP 2006-515994	20040617
US 2006178419	A1	20060810	US 2005-561328	20051219

PRIORITY APPLN. INFO.: GB 2003-14369 A 20030619
GB 2004-5774 A 20040315
WO 2004-EP6604 W 20040617

OTHER SOURCE(S): MARPAT 142:74444
GI



I

II

AB Title compds. represented by the formula I [wherein R1 = (un)substituted

L7 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CMF C20 H23 Cl F N3 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 811800-00-7 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[1-(4-morpholinyl)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811800-01-8 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[1-[(2-hydroxyethyl)methylamino]ethyl]phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L7 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

naphthyl, benzofuryl, phenyl(alkyl), etc.; R2 = H, alkyl, alkylamido, carbonylalkyl, etc.; X = (un)substituted Ph or arom. heterocyclic group; Y = (halo)alkylamino; and pharmaceutically acceptable derivs. thereof] were prepd. as inhibitors of factor Xa. For example, II was given in a multi-step synthesis starting from the reaction of 2-fluoro-4-iodoaniline with tert-Bu ((3S)-2-oxotetrahydro-3-furanyl)carbamate. The prepd. compds. showed activity in vitro assay for inhibition of factor Xa and in measurement of prothrombin time (PT) of human plasma. Thus, I and their pharmaceutical compns. are useful medicine, particularly in the amelioration of a clin. condition for which a factor Xa inhibitor is indicated (no data).

IT 811799-98-1P 811799-99-2P 811800-00-7P
811800-01-8P 811800-03-0P 811800-04-1P
811800-05-2P 811800-06-3P 811800-07-4P
811800-08-5P 811800-09-6P 811800-10-9P
811800-11-0P 811800-12-1P 811800-13-2P
811800-14-3P 811800-15-4P 811800-16-5P
811800-18-7P 811800-20-1P 811800-22-3P
811800-23-4P 811800-24-5P 811800-25-6P
811800-27-8P 811800-28-9P 811800-29-0P
811800-30-3P 811800-31-4P 811800-32-5P
811800-33-6P 811800-34-7P 811800-35-8P
811800-36-9P 811800-37-0P 811800-38-1P
811800-39-2P 811800-40-5P 811800-41-6P
811800-42-7P 811800-43-8P 811800-44-9P
811800-45-0P 811800-46-1P 811800-47-2P
811800-48-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(sulfonylamino)pyrrolidine-2-one derivs. as inhibitors of factor Xa)

RN 811799-98-1 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811799-99-2 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811799-98-1

L7 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811800-03-0 CAPLUS
CN Formic acid, compd. with (1E)-N-[(3S)-1-[4-(1-aminoethyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-02-9
CMF C18 H19 Cl F N3 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 811800-04-1 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[4-[1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811800-05-2 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[(1S)-1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811800-06-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-[(1S)-1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811800-07-4 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[4-[(1S)-1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811800-11-0 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[(1R)-1-(dimethylamino)ethyl]-2,6-difluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811800-12-1 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[(1S)-1-(dimethylamino)ethyl]-2,6-difluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811800-13-2 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[1-(dimethylamino)propyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811800-08-5 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[(1R)-1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811800-09-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-[(1R)-1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811800-10-9 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[4-[(1R)-1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811800-14-3 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[1-(dimethylamino)propyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-13-2
CMF C21 H25 Cl F N3 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 811800-15-4 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[1-(dimethylamino)-2-methylpropyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811800-16-5 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[1-(dimethylamino)-2-methylpropyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-15-4
CMF C22 H27 Cl F N3 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811800-18-7 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[1-(dimethylamino)-1-methylethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-17-6
CMF C21 H25 Cl F N3 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.

CM 1

CRN 811800-21-2
CMF C23 H25 Cl F N3 O3 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811800-23-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[4-[1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 811800-24-5 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[4-[1-(ethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 811800-25-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[4-[1-(ethylmethylamino)ethyl]-2-



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811800-20-1 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[4-[1-(dimethylamino)-1-methylethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-2-naphthalenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-19-8
CMF C25 H27 Cl F N3 O3 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811800-22-3 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[4-[1-(dimethylamino)-1-methylethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]benzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 811800-27-8 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[2-fluoro-4-[1-[methyl(1-methylethyl)amino]ethyl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 811800-28-9 CAPLUS
CN 2-Naphthalenesulfonamide, N-[1-[4-[1-(1-azetidinyl)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)



RN 811800-29-0 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[2-fluoro-4-[1-(1-pyrrolidinyl)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 811800-30-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[2-fluoro-4-[1-(1-piperidinyl)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 811800-31-4 CAPLUS
CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-1-[4-[1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811800-32-5 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[(1S)-1-(dimethylamino)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



CRN 811800-34-7
CMF C20 H24 Cl N3 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 811800-36-9 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[4-[(1S)-1-(dimethylamino)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811800-37-0 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[4-[(1S)-1-(dimethylamino)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]benzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-36-9
CMF C22 H24 Cl N3 O3 S2

Absolute stereochemistry.

RN 811800-33-6 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[(1S)-1-(dimethylamino)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-32-5
CMF C20 H24 Cl N3 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 811800-34-7 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[(1R)-1-(dimethylamino)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811800-35-8 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[(1R)-1-(dimethylamino)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 811800-38-1 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[4-[(1R)-1-(dimethylamino)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811800-39-2 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[4-[(1R)-1-(dimethylamino)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]benzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-38-1
CMF C22 H24 Cl N3 O3 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811800-40-5 CAPLUS
CN 1-Propene-1-sulfonamide, 2-(5-chloro-2-thienyl)-N-[1-[4-[1-(dimethylamino)ethyl]-2,6-difluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 811800-41-6 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[1-[4-[1-(dimethylamino)ethyl]-2,6-difluorophenyl]-2-oxo-3-pyrrolidinyl]-1-propene-1-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-40-5
CMF C21 H24 Cl F2 N3 O3 S2

Double bond geometry as shown.

CRN 64-18-6
CMF C H2 O2

RN 811800-44-9 CAPLUS
CN Ethenesulfonamide, N-[1-[4-(1-aminoethyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 811800-45-0 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[1-[4-[1-(dimethylamino)-1-methylethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 811800-46-1 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[4-[1-(dimethylamino)-1-methylethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 811800-47-2 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[1-[4-[1-(dimethylamino)-1-



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811800-42-7 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[1-[4-[1-(dimethylamino)ethyl]-2,6-difluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 811800-43-8 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[1-[4-[1-(dimethylamino)ethyl]-2,6-difluorophenyl]-2-oxo-3-pyrrolidinyl]benzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-42-7
CMF C22 H22 Cl F2 N3 O3 S2



CM 2

methylethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 811800-48-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[2-fluoro-4-[1-[(1-methylethyl)amino]ethyl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



IT 553651-70-0P 553651-94-8P 553653-26-2P
553653-27-3P 811799-51-6P 811799-52-7P
811799-53-8P 811799-81-2P 811799-82-3P
811799-83-4P 811799-84-5P 811799-86-7P
811799-87-8P 811800-26-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-(sulfonylamino)pyrrolidine-2-one derivs. as inhibitors of factor Xa)

RN 553651-70-0 CAPLUS
CN Ethenesulfonamide, N-[(3S)-1-(4-acetyl-2-fluorophenyl)-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-94-8 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-(1-hydroxyethyl)phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 553653-26-2 CAPLUS
CN Ethenesulfonamide, N-[(3S)-1-[4-(1-bromoethyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553653-27-3 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[1-(diformylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811799-51-6 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, N-[(3S)-1-(4-acetyl-2-fluorophenyl)-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811799-83-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811799-84-5 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811799-86-7 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[2-fluoro-4-(1-hydroxyethyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 811799-52-7 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1-hydroxyethyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811799-53-8 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, N-[(3S)-1-[4-(1-bromoethyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811799-81-2 CAPLUS
CN 2-Naphthalenesulfonamide, N-[(3S)-1-(4-acetyl-2-fluorophenyl)-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811799-82-3 CAPLUS



RN 811799-87-8 CAPLUS
CN 2-Naphthalenesulfonamide, N-[1-[4-(1-bromoethyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)



RN 811800-26-7 CAPLUS
CN 2-Naphthalenesulfonamide, N-[1-(4-acetyl-2-fluorophenyl)-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1124629 CAPLUS
DOCUMENT NUMBER: 142:74440
TITLE: Preparation of 3-(sulfonylamino)pyrrolidin-2-one derivatives as factor Xa inhibitors
INVENTOR(S): Borthwick, Alan David; Chan, Chuen; Kelly, Henry Anderson; Kleanthous, Savvas; Mason, Andrew Mcmurtrie; Watson, Nigel Stephen
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110435	A1	20041223	WO 2004-EP6592	20040617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1635817	A1	20060322	EP 2004-736979	20040617
EP 1635817	B1	20061122		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006527729	T	20061207	JP 2006-515988	20040617
AT 345795	T	20061215	AT 2004-736979	20040617
US 2006148879	A1	20060706	US 2005-561545	20051219

PRIORITY APPLN. INFO.: GB 2003-14299 A 20030619
WO 2004-EP6592 W 20040617

OTHER SOURCE(S): MARPAT 142:74440
GI



I II

L7 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB Title compds. represented by the formula I [wherein R1 = (un)substituted naphthyl, 2-benzofuryl, phenyl(alkyl), etc.; R2 = alkyl(cycloalkyl), alkylamino, alkoxyalkyl, etc.; with the proviso that R2 does not present alkylmorpholino; X = (un)substituted Ph or aromatic heterocyclic group; Y = H, halo, alkyl, amino, etc.; and pharmaceutically acceptable derivs. thereof] were prepared as inhibitors of factor Xa. For example, II was given in a multi-step synthesis starting from the reaction of 2-fluoro-4-iodoaniline with tert-Bu ((3S)-2-oxotetrahydro-3-furanyl)carbamate. The prepared compds. showed activity in vitro assay for inhibition of factor Xa with Ki values less than 0.1 μM, and in measurement of prothrombin time (PT) of human plasma. Thus, I and their pharmaceutical compns. are useful medicine, particularly in the amelioration of a clin. condition for which a factor Xa inhibitor is indicated (no data).

IT 811788-71-3P 811788-72-4P 811788-73-5P
811788-74-6P 811788-75-7P 811788-76-8P
811788-77-9P 811788-78-0P 811788-79-1P
811788-80-4P 811788-81-5P 811788-82-6P
811788-83-7P 811788-84-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(sulfonylamino)pyrrolidine-2-one derivs. as factor Xa inhibitors)

RN 811788-71-3 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl](cyclopropylmethyl)amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-72-4 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl][3-(dimethylamino)propyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-73-5 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl][2-(dimethylamino)ethyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-74-6 CAPLUS
CN Benzamide, 4-[(3S)-3-[[2-(2-amino-2-oxoethoxy)ethyl][[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-75-7 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]cyclopentylamino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L7 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811788-76-8 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl][(1-methyl-1H-imidazol-2-yl)methyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-77-9 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl](1-methylethyl)amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-78-0 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl](2-pyridinylmethyl)amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-79-1 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl][(3,5-dimethyl-4-isoxazolyl)methyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-80-4 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl](2-methoxyethyl)amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-81-5 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl][2-(1,1-dimethylethoxy)ethyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)



IT 553651-62-0P 553651-68-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-(sulfonylamino)pyrrolidine-2-one derivs. as factor Xa inhibitors)

RN 553651-62-0 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-68-6 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-82-6 CAPLUS
CN Benzamide, 4-[(3S)-3-[[(3-aminopyrazinyl)methyl][[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-83-7 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-84-8 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

ACCESSION NUMBER: 2004:1124628 CAPLUS
DOCUMENT NUMBER: 142:74439
TITLE: Preparation of 3-(sulfonylamino)pyrrolidine-2-one derivatives as factor Xa inhibitors
INVENTOR(S): Borthwick, Alan David; Kleanthous, Savvas; Senger, Stefan; Smith, Ian Edward David
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110434	A1	20041223	WO 2004-EP6591	20040617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1633347	A1	20060315	EP 2004-740039	20040617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006527728	T	20061207	JP 2006-515987	20040617

PRIORITY APPLN. INFO.: GB 2003-14370 A 20030619
WO 2004-EP6591 W 20040617

OTHER SOURCE(S): MARPAT 142:74439
GI



I II

AB Title compds. represented by the formula I [wherein R1 = (un)substituted naphthyl, 2-benzofuryl, thienylalkyl, phenyl(alkyl), etc.; R2 = H, alkyl, alkylamido, carbonylalkoxy, etc.; X = (un)substituted Ph or aromatic heterocyclic group; Y = absent or alkylene; and pharmaceutically

acceptable derivs. thereof] were prepd. as inhibitors of factor Xa. For example, II was given in a multi-step synthesis starting from the reaction of 2-fluoro-4-iodoaniline with tert-Bu ((3S)-2-oxotetrahydro-3-furanyl)carbamate. Most of the prepd. compds. showed activity in vitro assay for inhibition of factor Xa with Ki values of less than 1 μM. Thus, I and their pharmaceutical compns. are useful medicine, particularly in the amelioration of a clin. condition for which a factor Xa inhibitor is indicated (no data).

IT 811793-44-9P 811793-49-4P 811793-53-0P
811793-56-3P 811793-61-0P 811793-62-1P
811793-65-4P 811793-69-8P 811793-71-2P
811793-74-5P 811793-76-7P 811793-79-0P
811793-82-5P 811793-83-6P 811793-84-7P
811793-86-9P 811793-87-0P 811793-90-5P
811793-92-7P 811793-94-9P 811793-96-1P
811793-98-3P 811793-99-4P 811794-01-1P
811794-02-2P 811794-03-3P 811794-04-4P
811794-05-5P 811794-07-7P 811794-09-9P
811794-11-3P 811794-12-4P 811794-14-6P
811794-16-8P 811794-18-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-phenyl-3-(sulfonylamino)pyrrolidine-2-one derivs. as factor Xa inhibitors)

RN 811793-44-9 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-49-4 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(2-hydroxyethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-53-0 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-56-3 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-61-0 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(2-methoxyethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-62-1 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-65-4 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-69-8 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-71-2 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-74-5 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(2-hydroxyethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-76-7 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-79-0 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(2-methoxyethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-82-5 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-N-[2-(dimethylamino)ethyl]-3-fluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-83-6 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-84-7 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-2-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-86-9 CAPLUS
CN Benzamide, N-(2-amino-2-oxoethyl)-4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-87-0 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-90-5 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-92-7 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-[2-(1H-imidazol-4-yl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-94-9 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(3-hydroxypropyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-96-1 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[3-(methylamino)-3-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-98-3 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(5-methyl-1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-99-4 CAPLUS
CN Glycine, N-[4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorobenzoyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811794-01-1 CAPLUS
CN Glycine, N-[4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorobenzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811794-02-2 CAPLUS
CN Benzamide, 4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-N-[2-(dimethylamino)ethyl]-3-fluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811794-03-3 CAPLUS
CN Formic acid, compd. with 4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-N-[2-(dimethylamino)ethyl]-3-fluoro-N-methylbenzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-02-2
CMF C24 H26 Cl F N4 O4 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 811794-07-7 CAPLUS
CN Benzamide, 4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811794-09-9 CAPLUS
CN Benzamide, N-(2-aminoethyl)-4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811794-11-3 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 811794-04-4 CAPLUS
CN Benzamide, 4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811794-05-5 CAPLUS
CN Formic acid, compd. with 4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(methylamino)ethyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-04-4
CMF C23 H24 Cl F N4 O4 S2

Absolute stereochemistry.

propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-N-[2-(dimethylamino)ethyl]-3-fluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811794-12-4 CAPLUS
CN Formic acid, compd. with 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-N-[2-(dimethylamino)ethyl]-3-fluoro-N-methylbenzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-11-3
CMF C23 H28 Cl F N4 O4 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 811794-14-6 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811794-16-8 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-[2-(1H-imidazol-4-yl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811794-18-0 CAPLUS
CN Benzamide, 4-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 811794-25-9P 811794-28-2P 811794-29-3P
811794-30-6P 811794-31-7P 811794-36-2P
811794-38-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1-phenyl-3-(sulfonylamino)pyrrolidine-2-one derivs. as factor Xa inhibitors)
RN 811794-25-9 CAPLUS
CN Benzoic acid, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 811794-31-7 CAPLUS
CN Benzoic acid, 4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811794-36-2 CAPLUS
CN Benzoic acid, 4-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811794-38-4 CAPLUS
CN Benzoic acid, 4-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

Absolute stereochemistry.
Double bond geometry as shown.



RN 811794-28-2 CAPLUS
CN Benzoic acid, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811794-29-3 CAPLUS
CN Benzoic acid, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811794-30-6 CAPLUS
CN Benzoic acid, 4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:267295 CAPLUS
DOCUMENT NUMBER: 140:287260
TITLE: Preparation of 4-pyrrolidinophenyl benzyl ether derivatives as monoamine oxidase B inhibitors
INVENTOR(S): Jolidon, Synese; Rodriguez-Sarmiento, Rosa Maria; Thomas, Andrew William; Wostl, Wolfgang; Wyler, Rene
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026826	A1	20040401	WO 2003-EP10383	20030918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2498335	A1	20040401	CA 2003-2498335	20030918
AU 2003273901	A1	20040408	AU 2003-273901	20030918
US 2004097578	A1	20040520	US 2003-666594	20030918
US 2004106650	A1	20040603	US 2003-667088	20030918
US 7037935	B2	20060502		
US 2004116707	A1	20040617	US 2003-667087	20030918
US 7151111	B2	20061219		
EP 1542971	A1	20050622	EP 2003-757866	20030918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014314	A	20050726	BR 2003-14314	20030918
CN 1681777	A	20051012	CN 2003-821256	20030918
CN 1681778	A	20051012	CN 2003-821767	20030918
CN 1681779	A	20051012	CN 2003-821952	20030918
JP 2006503834	T	20060202	JP 2004-537120	20030918
NO 2005000701	A	20050302	NO 2005-701	20050209
ZA 2005001557	A	20050908	ZA 2005-1557	20050222
IN 2005CN00419	A	20070525	IN 2005-CN419	20050317
US 2006122235	A1	20060608	US 2006-325747	20060105
US 7122562	B2	20061017		
PRIORITY APPLN. INFO.:			EP 2002-21319 A	20020920
			US 2003-667088 A3	20030918
			WO 2003-EP10383 W	20030918

OTHER SOURCE(S): MARPAT 140:287260
GI



I

AB Title compds. I [R = (un)substituted Ph; X-Y = CH2CH2, CH:CH, CH2O; R1-R3 = H, halogen; R4 = H, halogen, Me; R5 = (un)substituted CONH2, NH2] were prepared for use in the prevention and treatment of illness mediated by monoamine oxidase B, in particular Alzheimer's disease or senile dementia (no data). Thus, 4-PhCH2OC6H4NH2 was treated with BrCH2CH2CHBrCOCl and the resulting amide cyclized with Dowex 2X10 to give 1-(4-benzyloxyphenyl)-3-bromo-2-pyrrolidinone which was treated with NaCN to give the 3-cyano analog.

IT 676232-70-5P 676232-73-8P 676232-74-9P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-pyrrolidinophenyl benzyl ether derivs. as monoamine oxidase B inhibitors)

RN 676232-70-5 CAPLUS
CN Methanesulfonamide, N-[(3S)-2-oxo-1-[4-(phenylmethoxy)phenyl]-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 676232-73-8 CAPLUS
CN Methanesulfonamide, N-[(3R)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 676232-74-9 CAPLUS
CN Methanesulfonamide, N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:20333 CAPLUS
DOCUMENT NUMBER: 140:93926
TITLE: Preparation of sulfonylaminovalerolactams as factor Xa inhibitors
INVENTOR(S): Smallheer, Joanne M.; Pinto, Donald J.; Wang, Shuaige; Qiao, Jennifer X.; Han, Wei; Hu, Zilun
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S. Pat. Appl. Publ., 89 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004006062	A1	20040108	US 2003-429461	20030505
US 7157470	B2	20070102		
WO 2004041776	A2	20040521	WO 2003-US14142	20030505
WO 2004041776	A3	20040910		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003301863	A1	20040607	AU 2003-301863	20030505
EP 1501798	A2	20050202	EP 2003-808359	20030505
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006247243	A1	20061102	US 2006-472825	20060621
PRIORITY APPLN. INFO.:			US 2002-378313P	P 20020506
			US 2003-429461	A3 20030505
			WO 2003-US14142	W 20030505

OTHER SOURCE(S): MARPAT 140:93926
GI

L7 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB The title compds. I [G = Ph, pyridyl, pyrrolyl, etc.; G1 = H, alkyl, acyl, (substituted) amino, etc.; A = (substituted) Ph, carbocyclic, heterocyclyl; B = lactam; heterocyclyl, etc.; n = 0-2] were prepared I can be used as inhibitors of trypsin-like serine proteases, specifically factor Xa. Thus, II is prepared from 1-[4-(3-amino-2-oxopiperidin-1-yl)-3-fluorophenyl]-piperidin-2-one (preparation given) and 6-chloronaphthalene-2-sulfonyl chloride. Pharmaceutical compds. containing I are described.

IT 641612-43-3P 641612-44-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonylaminovalerolactams as factor Xa inhibitors)

RN 641612-43-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[2-oxo-1-[4-(2-oxo-1-piperidinyl)phenyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 641612-44-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[2-oxo-1-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:777806 CAPLUS
DOCUMENT NUMBER: 139:292253
TITLE: Preparation of novel dithiolopyrrolones with therapeutic activity against proliferative diseases
INVENTOR(S): Chen, Genhui; Li, Bin; Li, Jianxiong; Webster, John
PATENT ASSIGNEE(S): Welichem Biotech Inc., Can.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080624	A2	20031002	WO 2003-CA380	20030318
WO 2003080624	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2479341	A1	20031002	CA 2003-2479341	20030318
AU 2003209899	A1	20031008	AU 2003-209899	20030318
EP 1490374	A2	20041229	EP 2003-744744	20030318
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1642959	A	20050720	CN 2003-806882	20030318
JP 2005526803	T	20050908	JP 2003-578378	20030318
IN 2004CN02153	A	20060303	IN 2004-CN2153	20040927
US 2006074125	A1	20060406	US 2005-509074	20051014
PRIORITY APPLN. INFO.:			US 2002-367265P	P 20020326
			US 2002-418698P	P 20021017
			WO 2003-CA380	W 20030318

OTHER SOURCE(S): MARPAT 139:292253
GI



I

II

L7 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB The present invention provides novel dithiolopyrrolone compds. (I) [X and Y can be the same or different, are hydrogen, substituted or unsubstituted alkyl, cycloalkyl, aryl, aralkyl or heterocyclic group except the compds. with: Z = Ph, Y = H, X = H, Me or benzyl, and Z = 4-pyridine, X = Me, Y = H; or When X = aryl, heterocyclic, Y and Z, can be the same or different, are hydrogen, unsubstituted or substituted or alkyl of two or less hydroxy groups and no carboxylic acid group, cycloalkyl, aryl, aralkyl or heterocyclic group, except the compds. with: Z = Me, Y = H, X = Ph, 4-methoxyphenyl, 4-methylphenyl] and their salts, which are useful as treatments for cancer and other proliferative diseases. The present invention also provides therapeutic compns. comprising particularly useful types of dithiolopyrrolones, the salts thereof, and methods of using the compds. within such types, particularly in treating proliferative diseases such as cancer. For example, 1,2-dithiolo[4,3-b]pyrrol-5(4H)-one derivative (II) in vitro showed IC50 of ≤0.01, 0.13, 0.016, 0.14, 0.014, 0.03, 0.04, 0.013, and 0.013 μM against leukemia CCRF-CEM, non-small cell lung cancer, colon cancer HCT-116, CNS cancer 0.14, melanoma LOXIMVI, ovarian cancer OVCAR-3, renal cancer RXF 393, prostate cancer DU-145, and breast cancer T-47D, resp.

IT 608132-34-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel dithiolopyrrolones with therapeutic activity against
proliferative diseases such as cancer)

RN 608132-34-9 CAPLUS

CN Methanesulfonamide, N-[1-(2,4-dimethoxyphenyl)-4-[(1,1-dimethylethyl)thio]-5-[[(1,1-dimethylethyl)thio]methylene]-2,5-dihydro-2-oxo-1H-pyrrol-3-yl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:511293 CAPLUS
DOCUMENT NUMBER: 139:85238
TITLE: Preparation of 3-(sulfonylamino)pyrrolidin-2-ones as factor Xa inhibitors
INVENTOR(S): Borthwick, Alan David; Chan, Chuen; Kelly, Henry Anderson; King, Nigel Paul; Kleanthous, Savvas; Mason, Andrew McMurtrie; Pinto, Ivan Leo; Pollard, Derek Roland; Senger, Stefan; Shah, Gita Punjabhai; Watson, Nigel Stephen; Young, Robert John
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053925	A1	20030703	WO 2002-EP14826	20021220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
TW 262075	B	20060921	TW 2002-91136597	20021219
CA 2471461	A1	20030703	CA 2002-2471461	20021220
AU 2002366747	A1	20030709	AU 2002-366747	20021220
EP 1456172	A1	20040915	EP 2002-805350	20021220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015200	A	20041013	BR 2002-15200	20021220
CN 1620434	A	20050525	CN 2002-828224	20021220
JP 2005519885	T	20050707	JP 2003-554642	20021220
HU 200500137	A2	20060228	HU 2005-137	20021220
NZ 533129	A	20061222	NZ 2002-533129	20021220
ZA 2004004147	A	20050621	ZA 2004-4147	20040527
IN 2004DN01467	A	20070209	IN 2004-DN1467	20040528
NO 2004002990	A	20040920	NO 2004-2990	20040713
US 2005059726	A1	20050317	US 2004-499529	20041101
PRIORITY APPLN. INFO.:			GB 2001-30705 A	20011221
			WO 2002-EP14826 W	20021220

OTHER SOURCE(S): MARPAT 139:85238
GI

L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I

II

AB Title compds. I [wherein R1 = (un)substituted naphthyl, benzothienyl, benzofuryl, indolyl, phenyl(alkyl), 2,2'-bithiophen-5-yl, thienyl(alkyl), or thieno[3,2-b]thiophenyl; R2 = H, (CH2)nCONRaRb, (CH2)nCO2Rc, morpholinoalkyl, CO2Rc, or carboxyalkyl; X = H, halo, CN, alkyl, alkenyl, CF3, NRaRb, NO2, NRcCHO, NHCORc, NHSO2Rc, alkoxyalkyl, hydroxyalkyl, CORc, CONRaRb, SO0-2Rc, SO2NRaRb, or (un)substituted Ph, heterocyclyl, or heteroaryl; n = 1-3; Ra and Rb = independently H or alkyl; or NRaRb = (un)substituted heterocyclyl; Rc = alkyl; and pharmaceutically acceptable derivs. thereof] were prepared as factor Xa inhibitors. For example, coupling of (3S)-3-amino-1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]pyrrolidin-2-one with 6-chloro-2-naphthylsulfonyl chloride in the presence of pyridine in DCM gave II. The latter inhibited human factor Xa in an in vitro fluorogenic assay with Ki <10 nM. Thus, I and compns. comprising I are useful as medicines for the amelioration of clin. conditions for which a Factor Xa inhibitor is indicated (no data).

IT 553650-65-0P 553650-67-2P, (S)-4'-[3-[[[(1E)-2-(5-Chlorothien-2-yl)prop-1-enyl]sulfonyl]amino]-2-oxopyrrolidin-1-yl]-3'-fluoro-1,1'-biphenyl-2-sulfonamide 553650-86-5P, (S)-3-Cyano-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]benzenesulfonamide 553651-02-8P, (S)-6-Chloro-N-[1-(2-fluoro-4-iodophenyl)-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-07-3P, (S)-6-Chloro-N-[1-[2-fluoro-4-(pyridin-4-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-60-8P 553651-65-3P 553651-70-0P, (S)-(E)-N-[1-(4-Acetyl-2-fluorophenyl)-2-oxopyrrolidin-3-yl]-2-(5-chlorothien-2-yl)ethenesulfonamide 553651-94-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(factor Xa inhibitor; preparation of (sulfonylamino)pyrrolidinone factor Xa
inhibitors starting from homoserines)

RN 553650-65-0 CAPLUS

CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-1-propene-1-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 553650-64-9
CMF C23 H25 Cl F N5 O3 S2

L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 553650-67-2 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3'-fluoro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 553650-86-5 CAPLUS

CN Benzenesulfonamide, 3-cyano-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-02-8 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-(2-fluoro-4-iodophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-07-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(4-pyridinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-60-8 CAPLUS
CN 2-Naphthalenesulfonamide, N-[(3S)-1-(4-bromo-2-fluorophenyl)-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)



IT 553650-48-9P, (S)-6-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553650-50-3P, (S)-6-Chloro-N-[1-(4-(dimethylamino)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553650-53-6P,
(S)-(E)-2-(5-Chlorothien-2-yl)-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]ethenesulfonamide 553650-54-7P
, (S)-5-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-1-benzofuran-2-sulfonamide 553650-55-8P,
(S)-N-[1-[3-Fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]isoquinoline-5-sulfonamide 553650-56-9P,
(S)-(E)-2-(4-Chlorophenyl)-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]ethenesulfonamide 553650-57-0P
, (S)-5'-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-2,2'-bithiophene-5-sulfonamide 553650-58-1P,
(S)-6-(Dimethylamino)-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553650-59-2P,
(S)-N-[1-[3-Fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]quinoline-8-sulfonamide 553650-60-5P, (S)-6-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-1-benzothiophene-2-sulfonamide 553650-61-6P, (S)-5-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-1-benzothiophene-2-sulfonamide 553650-63-8P 553650-66-1P
, (S)-N-[1-[2'-(Aminosulfonyl)-3-fluoro-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-6-chloro-1-benzothiophene-2-sulfonamide
553650-69-4P, (S)-(E)-2-(5-Chlorothien-2-yl)-N-[1-(3-fluoro-2'-nitro-1,1'-biphenyl-4-yl)-2-oxopyrrolidin-3-yl]ethenesulfonamide
553650-70-7P 553650-71-8P 553650-85-4P,
(S)-4-Cyano-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]benzenesulfonamide 553650-87-6P,
(S)-6-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-1-benzofuran-2-sulfonamide 553650-88-7P,
(S)-6-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]thieno[3,2-b]pyridine-2-sulfonamide
553650-89-8P, (S)-5-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]thieno[3,2-b]pyridine-2-sulfonamide
553650-90-1P, (S)-(1E)-2-(5-Chlorothien-2-yl)-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]prop-1-ene-1-sulfonamide 553650-96-7P 553650-97-8P
553650-98-9P 553650-99-0P 553651-00-6P
553651-01-7P 553651-05-1P, (S)-3-(Aminomethyl)-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]benzenesulfonamide 553651-06-2P, (S)-4-(Aminomethyl)-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]benzenesulfonamide 553651-08-4P, (S)-6-Chloro-N-[1-[4-(2,4-dimethoxypyrimidin-5-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-09-5P, (S)-6-Chloro-N-[1-[2-fluoro-4-(pyridin-3-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-10-8P, (S)-6-Chloro-N-[1-[2-fluoro-4-(6-methoxypyridin-3-

Absolute stereochemistry.



RN 553651-65-3 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-70-0 CAPLUS
CN Ethenesulfonamide, N-[(3S)-1-(4-acetyl-2-fluorophenyl)-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-94-8 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-(1-hydroxyethyl)phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-11-9P, (S)-6-Chloro-N-[1-[2-fluoro-4-(4-propylpyridin-3-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-12-0P, (S)-6-Chloro-N-[1-[2-fluoro-4-[6-(methylthio)pyridin-3-yl]phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-13-1P, (S)-N-[1-[4-(5-Bromopyridin-3-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]-6-chloronaphthalene-2-sulfonamide 553651-14-2P
, (S)-6-Chloro-N-[1-[2-fluoro-4-(4-methoxypyridin-3-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-15-3P,
(S)-6-Chloro-N-[1-[2-fluoro-4-(pyrimidin-5-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-16-4P, (S)-N-[1-[3'-(Aminomethyl)-3-fluoro-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-6-chloronaphthalene-2-sulfonamide 553651-17-5P,
(S)-6-Chloro-N-[1-[2-fluoro-4-(3-furyl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-18-6P, (S)-6-Chloro-N-[1-[2-fluoro-4-(4-methylthien-2-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-19-7P, (S)-6-Chloro-N-[1-[2-fluoro-4-(thien-3-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-20-0P, (S)-6-Chloro-N-[1-[2-fluoro-4-(5-methylthien-2-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-21-1P, (S)-6-Chloro-N-[1-[2-fluoro-4-[4-methylthien-3-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-22-2P, (S)-6-Chloro-N-[1-[2-fluoro-4-(3-formylthien-2-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-23-3P, (S)-6-Chloro-N-[1-[4-(5-chlorothien-2-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-24-4P, (S)-6-Chloro-N-[1-[4-(3,5-dimethylisoxazol-4-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-25-5P, (S)-6-Chloro-N-[1-[2-fluoro-4-(5-methyl-2-furyl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-26-6P, (S)-6-Chloro-N-[1-(3-fluoro-1,1'-biphenyl-4-yl)-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-28-8P
553651-29-9P, (S)-6-Chloro-N-[1-[2-fluoro-4-(1-oxidopyridin-4-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-30-2P, (S)-6-Chloro-N-[1-[2-fluoro-4-(1-methyl-1H-imidazol-2-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-32-4P, (S)-6-Chloro-N-[1-[4-(2-chloropyridin-3-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-35-7P, (S)-6-Chloro-N-[1-[4-(2-cyanopyridin-3-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-36-8P, (S)-(E)-N-[1-[4-(3-Chloropyridin-4-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]-2-(5-chlorothien-2-yl)ethenesulfonamide 553651-37-9P, (S)-6-Chloro-N-[1-[2-fluoro-4-(pyrimidin-2-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-38-0P, (S)-6-Chloro-N-[1-[4-(3-chloropyridin-2-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-39-1P, (S)-6-Chloro-N-[1-[4-(3-Chloropyridin-4-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-41-5P, (S)-6-Chloro-N-[1-[2-fluoro-4-(1-methyl-1H-imidazol-4-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide formate
553651-42-6P, (S)-6-Chloro-N-[1-[2-fluoro-4-(1-methyl-1H-imidazol-5-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-43-7P, (S)-2-(5-Chlorothien-2-yl)-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-1,3-thiazole-5-sulfonamide 553651-45-9P, (S)-5-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]thieno[3,2-b]thiophene-2-sulfonamide 553651-46-0P, (S)-2-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]thieno[3,2-b]thiophene-3-sulfonamide 553651-49-3P,
(S)-6-Chloro-N-[1-(2-fluoro-4-iodophenyl)-2-oxopyrrolidin-3-

yl]benzothiophene-2-sulfonamide 553651-50-6P
553651-51-7P, (S)-2-(5-Chloro-2-thienyl)-N-[1-(2-fluoro-4-iodophenyl)-2-oxopyrrolidin-3-yl]ethanesulfonamide 553651-52-8P
553651-53-9P, (S)-(E)-2-(5-Chloro-2-thienyl)-N-[1-(2-fluoro-4-nitrophenyl)-2-oxopyrrolidin-3-yl]ethenesulfonamide 553651-54-0P
553651-55-1P 553651-56-2P, (S)-(E)-2-(5-Chlorothien-2-yl)-N-[1-(4-cyano-2-fluorophenyl)-2-oxopyrrolidin-3-yl]ethenesulfonamide
553651-57-3P, (S)-2-(5-Chlorothien-2-yl)-N-[1-(4-cyano-2-fluorophenyl)-2-oxopyrrolidin-3-yl]ethanesulfonamide 553651-58-4P
, (S)-(E)-2-(5-Chloro-2-thienyl)-N-[1-(2-fluoro-4-isopropenylphenyl)-2-oxopyrrolidin-3-yl]ethenesulfonamide 553651-59-5P,
(S)-6-Chloro-N-[1-(2-fluorophenyl)-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-61-9P 553651-62-0P
553651-63-1P, (S)-(E)-2-(5-Chloro-2-thienyl)-N-[1-[2-fluoro-4-[1-pyrrolidinylcarbonyl]phenyl]-2-oxopyrrolidin-3-yl]ethenesulfonamide
553651-66-4P 553651-67-5P, (S)-4-[3-[[(6-Chlorobenzothien-2-yl)sulfonyl]amino]-2-oxopyrrolidin-1-yl]-3-fluoro-N,N-dimethylbenzamide 553651-68-6P 553651-69-7P,
(S)-4-[3-[[(6-Chlorobenzothien-2-yl)sulfonyl]amino]-2-oxopyrrolidin-1-yl]-3-fluoro-N-isopropyl-N-methylbenzamide 553651-72-2P
553651-73-3P 553651-74-4P 553651-75-5P
553651-76-6P 553651-77-7P, (S)-N-[4-[3-[[(6-Chlorobenzothien-2-yl)sulfonyl]amino]-2-oxopyrrolidinyl]-3-fluorophenyl]-2-methylpropanamide 553651-78-8P, (S)-(E)-2-(5-Chlorothien-2-yl)-N-[1-[2-fluoro-4-[formyl(isopropyl)amino]phenyl]-2-oxopyrrolidin-3-yl]ethenesulfonamide 553651-79-9P, (S)-6-Chloro-N-[1-[2-fluoro-4-[formyl(isopropyl)amino]phenyl]-2-oxopyrrolidin-3-yl]benzothiophene-2-sulfonamide 553651-80-2P, (S)-6-Chloro-N-[1-[2-fluoro-4-(1H-imidazol-1-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide
553651-82-4P, (S)-6-Chloro-N-[1-(2,4-dichlorophenyl)-2-oxopyrrolidin-3-yl]-2-naphthalenesulfonamide 553651-84-6P,
(S)-N-[1-(4-tert-Butylphenyl)-2-oxopyrrolidin-3-yl]-6-chloro-2-naphthalenesulfonamide 553651-87-9P, (S)-6-Chloro-N-[1-[2-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-oxopyrrolidin-3-yl]-2-naphthalenesulfonamide 553651-88-0P,
(S)-6-Chloro-N-[1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-oxopyrrolidin-3-yl]-2-naphthalenesulfonamide 553651-92-6P 553651-93-7P
553651-96-0P, (S)-(1E)-2-(5-Chlorothien-2-yl)-N-[1-[2-fluoro-4-[(methylsulfonyl)amino]phenyl]-2-oxopyrrolidin-3-yl]prop-1-ene-1-sulfonamide 553651-97-1P, (S)-(E)-N-[1-(4-Acetylphenyl)-2-oxopyrrolidin-3-yl]-2-(5-chlorothien-2-yl)ethenesulfonamide
553651-98-2P 553651-99-3P 553652-01-0P
553652-02-1P, (S)-2-(5-Chlorothien-2-yl)-N-[1-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxopyrrolidin-3-yl]ethanesulfonamide 553652-04-3P 553652-06-5P
553652-08-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(factor Xa inhibitor; prepn. of (sulfonylamino)pyrrolidinone factor Xa inhibitors starting from homoserines)

RN 553650-48-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-50-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(dimethylamino)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-53-6 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-54-7 CAPLUS
CN 2-Benzofuransulfonamide, 5-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-55-8 CAPLUS
CN 5-Isoquinolinesulfonamide, N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-56-9 CAPLUS
CN Ethenesulfonamide, 2-(4-chlorophenyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-57-0 CAPLUS
CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-58-1 CAPLUS
CN 2-Naphthalenesulfonamide, 6-(dimethylamino)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-59-2 CAPLUS
CN 8-Quinolinesulfonamide, N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-60-5 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



RN 553650-61-6 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-63-8 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]benzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 553650-62-7
CMF C24 H23 Cl F N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 553650-71-8 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-85-4 CAPLUS
CN Benzenesulfonamide, 4-cyano-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-87-6 CAPLUS
CN 2-Benzofuransulfonamide, 6-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

O=CH-OH

RN 553650-66-1 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, N-[(3S)-1-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-69-4 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-(3-fluoro-2'-nitro[1,1'-biphenyl]-4-yl)-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-70-7 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3'-fluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.





RN 553650-88-7 CAPLUS
CN Thieno[3,2-b]pyridine-2-sulfonamide, 6-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-89-8 CAPLUS
CN Thieno[3,2-b]pyridine-2-sulfonamide, 5-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-90-1 CAPLUS
CN 1-Propene-1-sulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-96-7 CAPLUS
CN Carbamic acid, [[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl][(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-97-8 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-N-[2-(4-morpholinyl)ethyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-98-9 CAPLUS
CN Acetamide, 2-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl][(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-99-0 CAPLUS
CN Glycine, N-[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-00-6 CAPLUS
CN Glycine, N-[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-01-7 CAPLUS
CN [1,1'-Biphenyl]-3-carboxamide, 4'-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-05-1 CAPLUS
CN Benzenesulfonamide, 3-(aminomethyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-06-2 CAPLUS
CN Benzenesulfonamide, 4-(aminomethyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-08-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(2,4-dimethoxy-5-pyrimidinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-09-5 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(3-pyridinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-10-8 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(6-methoxy-3-pyridinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-11-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(4-propyl-3-pyridinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-12-0 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-[6-(methylthio)-3-pyridinyl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-13-1 CAPLUS
CN 2-Naphthalenesulfonamide, N-[(3S)-1-[4-(5-bromo-3-pyridinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-14-2 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(4-methoxy-3-pyridinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-15-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(5-pyrimidinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-16-4 CAPLUS
CN 2-Naphthalenesulfonamide, N-[(3S)-1-[3'-(aminomethyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-17-5 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(3-furanyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-18-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(4-methyl-2-thienyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-19-7 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(3-thienyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-20-0 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(5-methyl-2-thienyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-21-1 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(4-methyl-3-thienyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-22-2 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(3-formyl-2-thienyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-23-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(5-chloro-2-thienyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-24-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(3,5-dimethyl-4-isoxazolyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-25-5 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(5-methyl-2-furanyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 553651-29-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1-oxido-4-pyridinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-30-2 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1-methyl-1H-imidazol-2-yl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-32-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(2-chloro-3-pyridinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-35-7 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(2-cyano-3-pyridinyl)-2-



RN 553651-26-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-(3-fluoro[1,1'-biphenyl]-4-yl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-28-8 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 553651-27-7
CMF C22 H23 Cl F N5 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-36-8 CAPLUS
CN Ethenesulfonamide, N-[(3S)-1-[4-(3-chloro-4-pyridinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-37-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(2-pyrimidinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-38-0 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(3-chloro-2-pyridinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-39-1 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(3-chloro-4-pyridinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-41-5 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[2-fluoro-4-(1-methyl-1H-imidazol-4-yl)phenyl]-2-oxo-3-pyrrolidinyl]-2-naphthalenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 553651-40-4
CMF C24 H20 Cl F N4 O3 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

Absolute stereochemistry.



RN 553651-49-3 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-(2-fluoro-4-iodophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-50-6 CAPLUS
CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-1-(2-fluoro-4-iodophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-51-7 CAPLUS
CN 2-Thiopheneethanesulfonamide, 5-chloro-N-[(3S)-1-(2-fluoro-4-iodophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-52-8 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3R)-1-(2-fluoro-4-

O=CH-OH

RN 553651-42-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1-methyl-1H-imidazol-5-yl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-43-7 CAPLUS
CN 5-Thiazolesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-45-9 CAPLUS
CN Thieno[3,2-b]thiophene-2-sulfonamide, 5-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-46-0 CAPLUS
CN Thieno[3,2-b]thiophene-3-sulfonamide, 2-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

nitrophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-53-9 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-(2-fluoro-4-nitrophenyl)-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-54-0 CAPLUS
CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-1-(2-fluoro-4-nitrophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-55-1 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-(4-cyano-2-fluorophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-56-2 CAPLUS

CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-(4-cyano-2-fluorophenyl)-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-57-3 CAPLUS
CN 2-Thiopheneethanesulfonamide, 5-chloro-N-[(3S)-1-(4-cyano-2-fluorophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-58-4 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-(1-methylethenyl)phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-59-5 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-(2-fluorophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-61-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-62-0 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-63-1 CAPLUS
CN Pyrrolidine, 1-[4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorobenzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-66-4 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-67-5 CAPLUS
CN Benzamide, 4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-68-6 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-69-7 CAPLUS
CN Benzamide, 4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-72-2 CAPLUS
CN Acetamide, N-[4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-73-3 CAPLUS
CN Propanamide, N-[4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-74-4 CAPLUS
CN Propanamide, N-[4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-75-5 CAPLUS
CN Acetamide, N-[4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-76-6 CAPLUS
CN Propanamide, N-[4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 553651-82-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-(2,4-dichlorophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-84-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(1,1-dimethylethyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-87-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-88-0 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

RN 553651-77-7 CAPLUS
CN Propanamide, N-[4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-78-8 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[formyl(1-methylethyl)amino]phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-79-9 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-[formyl(1-methylethyl)amino]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-80-2 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1H-imidazol-1-yl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.



RN 553651-92-6 CAPLUS
CN Benzamide, 4-[(3S)-3-[(2-amino-2-oxoethyl)[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-93-7 CAPLUS
CN Benzamide, 4-[(3S)-3-[(2-amino-2-oxoethyl)[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-96-0 CAPLUS
CN 1-Propene-1-sulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[(methylsulfonyl)amino]phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-97-1 CAPLUS
CN Ethenesulfonamide, N-[(3S)-1-(4-acetylphenyl)-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-98-2 CAPLUS
CN Acetamide, 2-[[1-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl][[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 553651-99-3 CAPLUS
CN Acetamide, 2-[[1-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl][[(1Z)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 553652-01-0 CAPLUS
CN Formic acid, compd. with 2-[[(3S)-1-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl][(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]acetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 553652-00-9
CMF C26 H22 Cl F N4 O6 S3

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 553652-02-1 CAPLUS
CN 2-Thiopheneethanesulfonamide, 5-chloro-N-[(3S)-1-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553652-04-3 CAPLUS
CN 1H-Imidazole-2-methanaminium, N-(2-amino-2-oxoethyl)-1-[4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]-N,N-dimethyl-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 553652-03-2
CMF C25 H29 Cl F N6 O4 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 71-47-6
CMF C H O2

O=CH-O-

RN 553652-06-5 CAPLUS
CN 1H-Imidazole-2-methanaminium, N-(2-amino-2-oxoethyl)-1-[4-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]-N,N-dimethyl-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 553652-05-4
CMF C24 H29 Cl F N6 O4 S2

Absolute stereochemistry.



CM 2

CRN 71-47-6
CMF C H O2

O=CH-O-

RN 553652-08-7 CAPLUS
CN 1H-Imidazole-2-methanaminium, N-(2-amino-2-oxoethyl)-1-[4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]-N,N-dimethyl-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 553652-07-6
CMF C26 H27 Cl F N6 O4 S2

Absolute stereochemistry.



CM 2

CRN 71-47-6
CMF C H O2

O=CH-O-

IT 553653-26-2P 553653-27-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of (sulfonylamino)pyrrolidinone factor Xa inhibitors starting from homoserines)

RN 553653-26-2 CAPLUS
CN Ethenesulfonamide, N-[(3S)-1-[4-(1-bromoethyl)-2-fluorophenyl]-2-oxo-3-

L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553653-27-3 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[1-(diformylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1994:245060 CAPLUS
DOCUMENT NUMBER: 120:245060
TITLE: Beta-carboline derivatives with anticholecystokinin activity, and their preparation, use, and pharmaceutical compositions
INVENTOR(S): Yamada, Koichiro; Hikota, Masataka; Yura, Takeshi; Shikano, Toshiro; Nagasaki, Masaaki
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 572235	A2	19931201	EP 1993-304083	19930526
EP 572235	A3	19940601		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 06041126	A	19940215	JP 1993-123668	19930526
CA 2097112	A1	19931129	CA 1993-2097112	19930527
US 5434148	A	19950718	US 1993-67931	19930527

PRIORITY APPLN. INFO.: JP 1992-136819 A 19920528
OTHER SOURCE(S): CASREACT 120:245060; MARPAT 120:245060
GI



I

AB Disclosed are β-carboline derivs. I, wherein R1 is H, alkyl, alkoxy, or OH; R5 is H; or R1R5 is alkylenedioxy; R2 is H, halo, alkoxy, or OH; R3 is H, carbamoylalkyl, alkyl, carboxyalkyl, or alkoxycarbonylalkyl; R4 is H, alkyl, carboxyalkyl, alkoxycarbonylalkyl, alkanoyl, arylcarbonyl, alkanesulfonyl, alkoxycarbonyl, aralkyl, formyl, or dialkylsulfamoyl; and n is 0, 1 or 2; and their pharmaceutically acceptable salts. Also claimed is a process for preparing I by formation of the bridging amide linkage, use of the compds. for prophylaxis or treatment of digestive diseases, and pharmaceuticals containing I. Examples include 85 invention compound syntheses and 48 precursor prepns. Thus, Friedel-Crafts cyclization of 4-MeOC6H4NHC6H4F-4 with oxalyl chloride gave 1-(4-fluorophenyl)-5-methoxy-1H-indole-2,3-dione, which reacted with NH2OH.HCl to give the 3-oxime. Hydrogenation of the latter to the 3-amino derivative, and amidation of this with β-carbolin-3-ylcarbonyl chloride, gave I [n = 0, R1 = 5-MeO, R2 = 4-F, R3 = R4 = R5 = H]. The compound I [n = 0, R3 = Me, other Rs = H] at 10 mg/kg i.v. in rats gave significant inhibition of pancreatic secretion induced by CCK-8 (no addnl. data). I are also said to show low toxicity.
IT 154059-19-5P

L7 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and abs. configuration of, in prepn. of CCK antagonists)
RN 154059-19-5 CAPLUS
CN Benzenesulfonamide, N-[1-(4-fluorophenyl)-2,3-dihydro-5-methoxy-3-methyl-2-oxo-1H-indol-3-yl]-4-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:485414 CAPLUS
DOCUMENT NUMBER: 119:85414
TITLE: 1,3,4-Trisubstituted pyrrolidinones as scaffolds for construction of peptidomimetic cholecystokinin antagonists
AUTHOR(S): Flynn, Daniel L.; Villamil, Clara I.; Becker, Daniel P.; Gullikson, Gary W.; Moummi, Chafiq; Yang, Dai Chang
CORPORATE SOURCE: Dep. Med. Chem., Searle Res. Dev., Skokie, IL, 60077, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1992), 2(10), 1251-6
CODEN: BMCLE8; ISSN: 0960-894X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A new series of cholecystokinin (CCK) antagonists are described which utilizes a new 1,3,4-trisubstituted pyrrolidinone as a scaffold for appending specific amino acid R group mimics. Several compds. (including SC-50998) exhibit potent nanomolar IC50 values in a CCK-A receptor binding assay. SC-50998 behaves as a competitive antagonist in vitro and is orally active.
IT 144024-01-1
RL: BIOL (Biological study)
(cholecystokinin A receptors antagonism by, structure in relation to)
RN 144024-01-1 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[(2-naphthalenylsulfonyl)amino]-5-oxo-1-phenyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1992:591677 CAPLUS
DOCUMENT NUMBER: 117:191677
TITLE: Preparation of pyrrolidinonecarboxylic acids and related compounds as cholecystokinin antagonists
INVENTOR(S): Becker, Daniel Paul; Flynn, Daniel Lee; Villamil, Clara Ines
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: PCT Int. Appl., 213 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9210476	A1	19920625	WO 1991-US8648	19911125
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MN, MW, NL, NO, PL, RO, SD, SE, SU, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
US 5202344	A	19930413	US 1990-626590	19901211
CA 2097517	A1	19920612	CA 1991-2097517	19911125
AU 9190571	A	19920708	AU 1991-90571	19911125
EP 561941	A1	19930929	EP 1992-901239	19911125
EP 561941	B1	19950104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06503827	T	19940428	JP 1991-502321	19911125
ES 2067322	T3	19950316	ES 1992-901239	19911125
US 5314886	A	19940524	US 1992-968617	19921029

PRIORITY APPLN. INFO.: US 1990-626590 A1 19901211
WO 1991-US8648 A 19911125

OTHER SOURCE(S): MARPAT 117:191677
GI


I


II

AB Title compds. I [Ar = (substituted) aryl, (substituted) heterocyclyl (substituted) bicyclic hydrocarbyl, etc.; R = C1-8 alkyl where 1 C atom may be replaced by O, (substituted) acyl, -aralkyl; X = bond, NH, O, C1-3 alkylene; n = 0, 1; R1, R1' = H, C1-4 alkyl; m = 0-3; R3 = OH, OR5; R5 = C1-6 alkyl, NR6R7; R6,R7 = H, C1-6 alkyl, NR8R9; R8,R9 = (substituted) C4-6 alkylene; R4 = H, C1-4 alkyl; Y = CO, SO2] were prepared as cholecystokinin (CCK) antagonists useful for treatment of CCK related disorders of the gastrointestinal tract, central nervous system, and appetite regulatory system. Thus, Et 4-amino-5-oxo-1-phenyl-3-pyrrolidinecarboxylate (preparation given) was amidated by 2-naphthoyl chloride and the product formed was hydrolyzed to give title compound II. II had IC50 of 0.015 μM against 125I-CCK-OP binding to rat pancreatic membranes.

L7 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 144024-01-1 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[(2-naphthalenylsulfonyl)amino]-5-oxo-1-phenyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 144023-98-3P 144023-99-4P 144024-00-0P
144024-01-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as cholecystokinin antagonist)

RN 144023-98-3 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[[(3,4-dichlorophenyl)sulfonyl]amino]-5-oxo-1-phenyl-, 1,1-dimethylethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 144023-99-4 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[(2-naphthalenylsulfonyl)amino]-5-oxo-1-phenyl-, 1,1-dimethylethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 144024-00-0 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[[(3,4-dichlorophenyl)sulfonyl]amino]-5-oxo-1-phenyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1990:118581 CAPLUS
DOCUMENT NUMBER: 112:118581
TITLE: Reactions of methyl esters of substituted 2-imino-3,3,3-trifluoropropionic acids with arylamines
AUTHOR(S): Osipov, S. N.; Chkanikov, N. D.; Kolomiets, A. F.; Fokin, A. V.
CORPORATE SOURCE: Inst. Elementoorg. Soedin, Moscow, USSR
SOURCE: Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1989), (7), 1648-52
CODEN: IASKA6; ISSN: 0002-3353
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 112:118581
GI


II

AB Treating PhNHR (R = H, Me) with CF3C(:NR1)CO2Me I (R1 = CF3CO, PhSO2, MeSO2) in khladon 113 6 h at 20° gave 65-70% PhNRC(CF3)(NHR1)CO2Me. Similarly, p-R2C6H4NHR (R = Me2CH, Ph, R2 = H, Me, OMe) and I (R1 as above) gave 15-60% indolinones II. PhNMe2 treated with I (R1 = CF3CO, MeSO2) gave 60 and 53% p-Me2NC6H4C(CF3)(NHR1)CO2Me.

IT 125535-61-7P 125535-62-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 125535-61-7 CAPLUS
CN Benzenesulfonamide, N-[2,3-dihydro-2-oxo-1-phenyl-3-(trifluoromethyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



RN 125535-62-8 CAPLUS
CN Methanesulfonamide, N-[2,3-dihydro-2-oxo-1-phenyl-3-(trifluoromethyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	90.53	435.39

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-13.26	-13.26

STN INTERNATIONAL LOGOFF AT 12:17:27 ON 15 JUN 2007